文献速递淋巴瘤

高危儿童霍奇金淋巴瘤患者在接受儿童肿瘤协作组AHOD 1331研究治疗期间的健康相关生活质量纵向评估

Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study.
PubMed 文献 · J Clin Oncol · 2024-07-26

该研究为AHOD 1331试验的预设纵向患者报告结局子研究,纳入268例11岁以上高危儿童霍奇金淋巴瘤患者,在治疗前及第2、5周期和治疗结束时用CHRIs-Global量表评估健康相关生活质量。结果显示,含维布妥昔单抗方案的HRQoL改善更早、幅度更大,标准方案至治疗结束才出现有临床意义的改善。

要点

  • 含维布妥昔单抗组在第2周期即出现统计学和有临床意义的HRQoL改善(β=7.3)。
  • 标准方案组至治疗结束才出现统计学和有临床意义的HRQoL改善(β=9.3)。
  • 两臂变化差异未达统计学显著(β=5.1,95%CI -0.2至10.3,P=.057)。

核心结论

  • 治疗期间儿童高危霍奇金淋巴瘤患者的系列HRQoL可成功采集,且初始治疗过程中HRQoL改善,接受新型药物维布妥昔单抗组改善更早、幅度更大。

研究设计与样本

  • AHOD 1331试验的预设纵向患者报告结局子研究,治疗随机分组后纳入268例11岁以上参与者,使用7条目CHRIs-Global量表在治疗前(T1)、第2周期(T2)、第5周期(T3)和治疗结束(T4)评估HRQoL。

主要发现

  • T1时93%参与者完成CHRIs,T2为92%,T3为89%,T4为77%。
  • T1时女性性别和发热(P<.05)分别与更差HRQoL相关。
  • 维布妥昔单抗组至T2时HRQoL改善(β=7.3 [95%CI 3.2至11.4];P≤.001),达到统计学和有临床意义。
  • 标准方案组至T4才出现统计学和有临床意义的HRQoL改善(β=9.3 [95%CI 4.7至11.5];P<.001)。

关键数值与推荐

  • HRQoL有临床意义的升高定义为CHRIs-Global量表7分。
  • 两臂变化差异为β=5.1(95%CI -0.2至10.3;P=.057)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSEThere have been no previous longitudinal assessments of health-related quality of life (HRQoL) during treatment for pediatric Hodgkin lymphoma (HL). The addition of brentuximab vedotin (BV) to a multidrug chemotherapy backbone demonstrated superior efficacy to standard chemotherapy for patients with pediatric high-risk HL in the AHOD 1331 trial. However, the impact on HRQoL is unknown.PATIENTS AND METHODSAfter treatment random assignment, 268 participants older than 11 years were enrolled in a prespecified, longitudinal, patient-reported outcomes substudy. HRQoL was assessed using the seven-item Child Health Ratings Inventories (CHRIs)-Global scale before treatment (T1) and at cycle 2 (T2), cycle 5 (T3), and end of treatment (T4). A clinically meaningful increase in HRQoL was considered 7 points on the CHRIs-Global. Multivariable linear regression estimated associations between demographic/clinical variables and HRQoL at T1. Linear mixed models estimated changes in HRQoL across the treatment arm.RESULTSParticipant characteristics were balanced by treatment arm. Ninety-three percent of participants completed the CHRIs at T1, 92% at T2, 89% at T3, and 77% at T4. At T1, female sex and fever (P < .05) were each associated with worse HRQoL. By T2, participants in the BV arm experienced a statistically and clinically significant improvement in HRQoL (β = 7.3 [95% CI, 3.2 to 11.4]; P ≤ .001), which was greater than the change in the standard arm (difference in change β = 5.1 [95% CI, -0.2 to 10.3]; P = .057). The standard arm did not experience a statistically or clinically significant increase in HRQoL until T4 (β = 9.3 [95% CI, 4.7 to 11.5]; P < .001).CONCLUSIONThese data demonstrate successful collection of serial HRQoL from youth with high-risk pediatric HL and improvement in HRQoL over the course of initial therapy, sooner and to a greater extent in the group receiving the novel agent BV.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Williams AM, Rodday AM, Pei Q, et al. Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study. J Clin Oncol. 2024. PMID: 39058966. doi:10.1200/JCO.24.00038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。